(VIANEWS) - Equus Total Return (EQS), Southside Bancshares (SBSI), DexCom (DXCM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 9.4% return on equity
Equus Total Reward, Inc., a business development firm (BDC), specializes in management buyouts and leveraged buyouts. It also offers equity and equity-oriented securities from privately held companies. It acts as an investor lead and invests in companies from small to medium size. The fund invests in alternative energy, real-estate, healthcare, education and e-learning. It also supports foreign investments in Europe, the United States and China. Common and preferred stock are all investments. The debt can be converted into preferred stock or common stock. There is also debt that comes with options and warrants. Other rights include the right to purchase common stock or preferred stock. This fund invests in businesses with annual revenues of between $10 and $100 million. Equus Total Reward, Inc. was established in Houston Texas in 1991. It also has a Vancouver office.
Earnings Per Share
As for profitability, Equus Total Return has a trailing twelve months EPS of $-0.909.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.4%.Volume
Today's last reported volume for Equus Total Return is 5246 which is 62.02% below its average volume of 13815.
Sales Growth
Equus Total Return's sales growth is 139.2% for the current quarter and 139.2% for the next.
Yearly Top and Bottom Value
Equus Total Return's stock is valued at $1.55 at 06:22 EST, way below its 52-week high of $2.72 and way higher than its 52-week low of $1.34.
Moving Average
Equus Total Return's value is way under its 50-day moving average of $1.90 and way below its 200-day moving average of $2.33.2. Southside Bancshares (SBSI)
18.8% sales growth and 13.33% return on equity
Southside Bancshares, Inc. is the bank holding company of Southside Bank. It provides financial services for individuals, businesses, municipalities, as well as nonprofits. The deposit products offered by the bank include checking, savings, money market and interest bearing and noninterest bearing accounts. Certificates of deposit are also available. Its loan portfolio includes consumer loans such as residential loans to 1-4 families, home equity loans and home improvements loans. Commercial loans include short-term working capital loans to inventory or accounts receivable, equipment loans and short- and medium-term loans for business capital expansion. Municipal loans and short-term loans for commercial real property loans. Construction loans are available for residential real estate and residential 1-4 families. The company also provides wealth management services, including administration, trust, trust, and investment management. It can provide safe deposit services, brokerage services, as well as custodian and custody services to individuals, corporations, partnerships and companies. The company had 56 banks and 73 ATMs/ITMs as of December 31, 2021. Southside Bancshares, Inc., was established in 1960. It is located in Tyler, Texas.
Earnings Per Share
As for profitability, Southside Bancshares has a trailing twelve months EPS of $3.34.
PE Ratio
Southside Bancshares has a trailing twelve months price to earnings ratio of 10.61. Meaning, the purchaser of the share is investing $10.61 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.33%.Sales Growth
Southside Bancshares's sales growth for the next quarter is 18.8%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 16, 2022, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 3.84%.
Growth Estimates Quarters
The company's growth estimates for the present quarter is a negative 2.2% and positive 2.3% for the next.Moving Average
Southside Bancshares's value is under its 50-day moving average of $38.37 and way below its 200-day moving average of $39.77.3. DexCom (DXCM)
16.5% sales growth and 7.9% return on equity
DexCom, Inc., is a medical device firm that focuses on continuous glucose monitoring systems (CGMs) in the United States as well as internationally. It offers its products for both diabetes patients and healthcare professionals. DexCom G6, a CGM system that integrates with diabetes management, Dexcom Real Time API which allows third-party developers access real-time CGM data in their digital health apps and devices, Dexcom ONE, designed to replace fingerstick blood glucose testing to aid diabetes treatment decisions, and Dexcom Share, a remote monitoring and control system. Dexcom G7 is the next-generation G7 CGM systems. DexCom, Inc. is a partner and licensed agreement with Verily Life Sciences LLC, and Verily Ireland Limited for the development of blood-based and interstitial glucose monitoring devices. It sells its products to diabetes educators, doctors, and endocrinologists. DexCom, Inc., was founded in 1999. It is located in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $5.2.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 19. Meaning, the purchaser of the share is investing $19 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.9%.4. Amphastar Pharmaceuticals (AMPH)
15.4% sales growth and 17.97% return on equity
Amphastar Pharmaceuticals, Inc., is a specialty pharmaceutical firm that develops, manufactures, market and sells intranasal, injectable, and inhalation products. It operates in France, China, the United States, and France. Two segments of the company are Finished Pharmaceutical Products (API) and Other Products (FPP). The company offers Primatene Mist (an over-the-counter epinephrine injection product to temporarily relieve mild symptoms of intermittent asthma); Enoxaparin (a low-molecular-weight heparin that prevents and treats deep vein thrombosis); Naloxone for opioid addiction; Glucagon emergency kit; Cortrosyn (a lyophilized powder used in diagnosis of patients suffering from adrenocortical impairment). Amphadase is a bovine-sourced, injectable hyaluronidase that can absorb and disperse other drugs. Epinephrine injections are used to treat allergic reactions. Lidocaine jelly for anesthesia for urological procedures. The topical solutions for many procedures include lidocaine, lidocaine, and phytonadione. There are also emergency syringes for hospital use. Morphine injections for patient controlled analgesia pumps. It also offers Procainamide to relieve documented arrhythmias, neostigmine, a methylsulfate injection, to treat myasthenia Gravis, and reverse the effects muscle relaxants, and medroxyprogesterone topical solution for various procedures. The company serves healthcare facilities, alternative care sites, clinics and doctor's offices. Rancho Cucamonga is the headquarters of this company, which was established in 1996.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $0.03.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 970. Meaning, the purchaser of the share is investing $970 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.97%.Sales Growth
Amphastar Pharmaceuticals's sales growth for the next quarter is 15.4%.
Volume
Today's last reported volume for Amphastar Pharmaceuticals is 139991 which is 51.87% below its average volume of 290907.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals's stock is valued at $29.10 at 06:22 EST, way under its 52-week high of $44.46 and way above its 52-week low of $18.12.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.8%, now sitting on 455.12M for the twelve trailing months.
5. Ducommun Incorporated (DCO)
10.8% sales growth and 31.51% return on equity
Ducommun Incorporated offers engineering and manufacturing services to the United States' aerospace, defense and industrial industries. The company operates in two sections, Electronic Systems and Structural Systems. Electronic Systems provides interconnect and cable assemblies as well as printed circuit boards assemblies. It also offers higher-level electromechanical and mechanical components as well as lightning diversion system. The Electronic Systems segment also offers engineered products such as illuminated pushbutton buttons and panels for testing and aviation; micro- and millimeter switches, filters for radio frequency system and test instruments; motors and resolvers to control motion. This segment also provides expertise in aerospace system design, engineering, integration and testing. Structural systems segment design, engineers and manufactures aluminum, titanium and Inconel aerostructure components. It also produces structural assemblies products such as fuselage structural panels, engine parts, and winglets. Metal and composite bonded structural structures and assemblies consisting of aircraft wing spoilers and large fuselage skins. The company serves military, commercial, and rotary-wing commercial aircraft as well as space and industrial markets. Santa Ana is the headquarters of this company, which was established in 1849.
Earnings Per Share
As for profitability, Ducommun Incorporated has a trailing twelve months EPS of $10.77.
PE Ratio
Ducommun Incorporated has a trailing twelve months price to earnings ratio of 3.82. Meaning, the purchaser of the share is investing $3.82 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.51%.Yearly Top and Bottom Value
Ducommun Incorporated's stock is valued at $41.10 at 06:22 EST, way below its 52-week high of $58.18 and higher than its 52-week low of $38.89.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ducommun Incorporated's EBITDA is 50.69.
Sales Growth
Ducommun Incorporated's sales growth is 10.3% for the ongoing quarter and 10.8% for the next.
6. Autodesk (ADSK)
9.8% sales growth and 53.97% return on equity
Autodesk, Inc. offers 3D engineering, entertainment, and design software worldwide. AutoCAD Civil 3D is a 3D design, engineering, and documentation software and service provider. It offers Inventor software that allows for 3D mechanical designs, analysis, visualization, tooling and documentation. Vault is a data management program to store data, speed up design processes and reduce collaboration. Maya and 3ds Max products offer 3D modeling and animation. ShotGrid can be used for production monitoring and review in media and entertainment. The company sells products and services directly to its customers as well as via a network distributors and resellers. Autodesk, Inc., was founded in 1982. It is located in San Rafael, California.
Earnings Per Share
As for profitability, Autodesk has a trailing twelve months EPS of $5.44.
PE Ratio
Autodesk has a trailing twelve months price to earnings ratio of 38. Meaning, the purchaser of the share is investing $38 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 53.97%.Moving Average
Autodesk's worth is above its 50-day moving average of $203.31 and above its 200-day moving average of $206.31.Revenue Growth
Year-on-year quarterly revenue growth grew by 16.7%, now sitting on 4.74B for the twelve trailing months.
Yearly Top and Bottom Value
Autodesk's stock is valued at $206.74 at 06:22 EST, way below its 52-week high of $335.48 and way higher than its 52-week low of $163.20.
7. Genuine Parts Company (GPC)
9.8% sales growth and 34.52% return on equity
Genuine Parts Company supplies automotive parts as well as industrial parts. The company operates in two segments: Automotive Parts Group, and Industrial Parts Group. It distributes replacement parts for vehicles such as hybrids and electrics. The company also sells replacement parts for industrial applications and supplies such as bearings and mechanical power transmission products. It also supplies hoses and hydraulic components. The company also offers various repairs, including hydraulic panel repair and assembly, fluid power pump repair and maintenance, electrical drive shaft assembly and repair and hose and gasket manufacturing and assembly. The company operates across the United States and Canada. It was founded in 1928 in Atlanta, Georgia.
Earnings Per Share
As for profitability, Genuine Parts Company has a trailing twelve months EPS of $0.37.
PE Ratio
Genuine Parts Company has a trailing twelve months price to earnings ratio of 467.21. Meaning, the purchaser of the share is investing $467.21 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.52%.Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 31, 2022, the estimated forward annual dividend rate is 3.58 and the estimated forward annual dividend yield is 2.21%.
Volume
Today's last reported volume for Genuine Parts Company is 1131990 which is 23.41% above its average volume of 917203.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 21.38B for the twelve trailing months.
8. The Travelers Companies (TRV)
7.1% sales growth and 13.7% return on equity
Through its affiliates, The Travelers Companies, Inc. provides commercial and personal property, as well as casualty, insurance products and services for individuals, businesses, governments, organizations, and associations throughout the United States and abroad. There are three main segments to the company: Personal Insurance, Bond & Specialty Insurance and Business Insurance. Workers' compensation, property and commercial vehicles, general liability and public liability are all offered by the Business Insurance segment. Other products include professional indemnity and marine, aviation and onshore energy. The segment is available through several accounts. These accounts include small and medium-sized companies, large businesses and large national accounts. It also serves large customers through national accounts. National property includes national and large accounts. This segment markets its products via wholesale agents and brokers. Bond & Specialty Insurance provides certainty, fidelity and management, as well as other coverages for property and casualty and associated risk management services, through independent agents and brokers. Independent brokers and agencies offer personal insurance that covers property and casualty risks. This includes homeowners and automobile insurance. Travelers Companies, Inc. is an American company that was established in New York, New York in 1853.
Earnings Per Share
As for profitability, The Travelers Companies has a trailing twelve months EPS of $11.06.
PE Ratio
The Travelers Companies has a trailing twelve months price to earnings ratio of 16.2. Meaning, the purchaser of the share is investing $16.2 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.7%.Moving Average
The Travelers Companies's worth is way higher than its 50-day moving average of $162.85 and above its 200-day moving average of $168.50.Growth Estimates Quarters
The company's growth estimates for the ongoing quarter and the next is a negative 3.5% and a negative 16.5%, respectively.Sales Growth
The Travelers Companies's sales growth is 7.9% for the current quarter and 7.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 35.76B for the twelve trailing months.